MedPage Today -- ORLANDO -- A poor-prognosis form of renal cell cancer demonstrated responsiveness to chemotherapy with doxorubicin and gemcitabine (Gemzar), according to data from a small clinical study.Action
MedPage Today -- ORLANDO -- A poor-prognosis form of renal cell cancer demonstrated responsiveness to chemotherapy with doxorubicin and gemcitabine (Gemzar), according to data from a small clinical study.Action